Generic pains for AstraZeneca exacerbated by Indian drugmakers The Pharma Letter Already reeling under the loss of its respiratory heavyweight Symbicort (budesonide and formoterol), whose key patents expired recently, the company might find it difficult to weather the generic storm ahead, reports The Pharma Letter's India ... |
